Literature DB >> 12797483

Upregulated response to chemokines in oxidative metabolism of eosinophils in asthma and allergic rhinitis.

S Sannohe1, T Adachi, K Hamada, K Honda, Y Yamada, N Saito, C H Cui, H Kayaba, K Ishikawa, J Chihara.   

Abstract

Reactive oxygen species (ROS) from eosinophils are known to cause tissue damage in allergic inflammation. CC chemokines, especially eotaxin and regulated on activation, normal T-cell expressed and secreted (RANTES), are involved not only in chemotaxis but also in eosinophil activation, such as ROS production. It has been shown that eosinophils from allergic patients are not functionally equivalent to those from normal subjects. In the present study, the characteristics of chemokine-primed ROS production in eosinophils from allergic patients and normal controls were compared. After pretreatment with chemokines, eosinophils were stimulated with calcium ionophore A23187. ROS production by eosinophils was measured using luminol-dependent chemiluminescence. Both RANTES and eotaxin exhibited a priming effect on calcium ionophore-induced ROS production from eosinophils. Despite there being no difference in expression of CC chemokine receptor 3, the priming effect of RANTES and eotaxin was significantly enhanced in eosinophils from the patients. Interleukin-5 further enhanced the priming effect of chemokines in eosinophils from normal subjects, but not those from allergic subjects. The present results suggest an upregulated response to chemokines in eosinophils from allergic patients, and that interleukin-5 can induce a similar phenotype to that found in vivo in allergic patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797483     DOI: 10.1183/09031936.03.00028103a

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

Review 1.  Airway smooth muscle in the pathophysiology and treatment of asthma.

Authors:  Diana C Doeing; Julian Solway
Journal:  J Appl Physiol (1985)       Date:  2013-01-10

Review 2.  Activation states of blood eosinophils in asthma.

Authors:  M W Johansson
Journal:  Clin Exp Allergy       Date:  2014-04       Impact factor: 5.018

3.  Administration of vitamin E attenuates airway inflammation through restoration of Nrf2 in a mouse model of asthma.

Authors:  Quang Luu Quoc; Tra Cao Thi Bich; Seo-Hee Kim; Hae-Sim Park; Yoo Seob Shin
Journal:  J Cell Mol Med       Date:  2021-06-04       Impact factor: 5.310

4.  Functional activity of peripheral blood eosinophils in allergen-induced late-phase airway inflammation in asthma patients.

Authors:  Simona Lavinskiene; Kestutis Malakauskas; Jolanta Jeroch; Deimante Hoppenot; Raimundas Sakalauskas
Journal:  J Inflamm (Lond)       Date:  2015-03-29       Impact factor: 4.981

5.  Hydrogen-rich saline attenuates eosinophil activation in a guinea pig model of allergic rhinitis via reducing oxidative stress.

Authors:  Shaoqing Yu; Chuanliang Zhao; Na Che; Lin Jing; Rongming Ge
Journal:  J Inflamm (Lond)       Date:  2017-01-13       Impact factor: 4.981

Review 6.  Possible Mechanisms of Eosinophil Accumulation in Eosinophilic Pneumonia.

Authors:  Kazuyuki Nakagome; Makoto Nagata
Journal:  Biomolecules       Date:  2020-04-21

7.  Asthma exacerbation related to viral infections: An up to date summary.

Authors:  Mehdi Adeli; Tamara El-Shareif; Mohamed A Hendaus
Journal:  J Family Med Prim Care       Date:  2019-09-30

Review 8.  Comprehensive overview of COVID-19-related respiratory failure: focus on cellular interactions.

Authors:  Fahimeh Zamani Rarani; Mohammad Zamani Rarani; Michael R Hamblin; Bahman Rashidi; Seyed Mohammad Reza Hashemian; Hamed Mirzaei
Journal:  Cell Mol Biol Lett       Date:  2022-07-30       Impact factor: 8.702

9.  Regulation of nasal airway homeostasis and inflammation in mice by SHP-1 and Th2/Th1 signaling pathways.

Authors:  Seok Hyun Cho; Sun Young Oh; Andrew P Lane; Joan Lee; Min-Hee Oh; Seakwoo Lee; Tao Zheng; Zhou Zhu
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.